These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 35667515)

  • 1. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.
    Zhang HP; Jiang RY; Zhu JY; Sun KN; Huang Y; Zhou HH; Zheng YB; Wang XJ
    Breast Cancer; 2024 Jul; 31(4):539-551. PubMed ID: 38630392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.
    Massihnia D; Galvano A; Fanale D; Perez A; Castiglia M; Incorvaia L; Listì A; Rizzo S; Cicero G; Bazan V; Castorina S; Russo A
    Oncotarget; 2016 Sep; 7(37):60712-60722. PubMed ID: 27474173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
    Cao W; Li J; Hao Q; Vadgama JV; Wu Y
    Breast Cancer Res; 2019 Feb; 21(1):29. PubMed ID: 30791936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple negative breast cancer: special histological types and emerging therapeutic methods.
    Cao L; Niu Y
    Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways: PI3K pathway targets in triple-negative breast cancers.
    Gordon V; Banerji S
    Clin Cancer Res; 2013 Jul; 19(14):3738-44. PubMed ID: 23748695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.
    James N; Owusu E; Rivera G; Bandyopadhyay D
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology and Management of Patients With Triple-Negative Breast Cancer.
    Sharma P
    Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
    Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
    Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.
    Fink LS; Beatty A; Devarajan K; Peri S; Peterson JR
    Mol Cancer Ther; 2015 Jan; 14(1):298-306. PubMed ID: 25344583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
    Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
    Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.